Andrei Salca
YOU?
Author Swipe
View article: Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer
Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer Open
PARP inhibitors (PARPi) are approved treatments for patients with metastatic prostate cancer (mPC); tumors with homologous recombination repair (HRR) defects are particularly sensitive to this drug class. While previous work has associated…
The transcriptional landscape of metastatic hormone-naïve prostate cancer Open
Metastatic hormone-naïve prostate cancer (mHNPC) is an infrequent form of this tumour type that is characterized by metastasis at the time of diagnosis and accounts for 50% of prostate cancer-related deaths. Despite the extensive character…